<DOC>
	<DOC>NCT01133704</DOC>
	<brief_summary>This is a randomized, double blind, placebo controlled trial of immunotherapy with autologous antigen-loaded dendritic cells (Provenge, APC8015) for asymptomatic, metastatic, hormone-refractory prostate cancer.</brief_summary>
	<brief_title>Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Histologically documented adenocarcinoma of the prostate Metastatic disease as evidenced by soft tissue and/or bony metastases Prostatespecific antigen value of at least 5 ng/mL Tumor progression while on hormonal therapy Castration levels of testosterone (defined as less than 50 ng/dL) Life expectancy of at least 16 weeks Adequate hematologic, renal, and liver function Visceral organ metastases Metastatic disease expected to be in need of radiation therapy within 4 months. Concurrent therapy with experimental agents</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>asymptomatic metastatic hormone-refractory prostate cancer</keyword>
</DOC>